Special Update - PCYC – Imbruvica’s Flies To Blockbuster Status; Solid Tumor/I-O Potential Even Larger – Raising TARGET PRICE – At the JPM presentation, PCYC surprised everyone with guidance for Imbruvica sales. The Company, one of the most conservative with regards to public forecasts, had not previously provided any number with regards to Imbruvica sales. Moreover, [...]
BioInvest In The News
(for subscribers only) Listen to the ‘Access to Management’ Conference Call we had with the Novavax Management Team on Friday, December 19, 2014 where we discussed what’s in the Novavax pipeline, offered a brief R&D Summary and had a Q&A session with subscribers.
Special ASH Update for ISIS ISIS Factor XI Data Published in NEJM, 2nd Time in One Week: Isis has been an unexpected star at ASH as they have released the final Phase II data for ISIS-FXI at ASH and were also published in the New England Medical Journal. The data showed a significant reduction (seven-fold [...]